

**To:** Office of Attorney General  
[AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov)

**From:** Mylan Institutional Inc.  
1000 Mylan Boulevard  
Canonsburg, Pennsylvania 15317

**Date:** September 11, 2019

**Re:** 18 V.S.A § 4637

---

In compliance with 18 V.S.A. § 4637, Mylan Institutional Inc. hereby provides written notice that on September 9, 2019 it introduced the following new generic prescription drug to market:

- Fulvestrant 50mg/mL 5mL PFS 2PK